![](/images/smile/35.jpg)
![](/images/smile/209.jpg)
![](/images/smile/78.jpg)
![](/images/smile/276.jpg)
![](/images/smile/117.jpg)
![](/images/smile/318.jpg)
![](/images/smile/58.jpg)
![](/images/smile/277.jpg)
![](/images/smile/44.jpg)
![](/images/smile/176.jpg)
![](/images/smile/56.jpg)
![](/images/smile/253.jpg)
![](/images/smile/51.jpg)
![](/images/smile/214.jpg)
![](/images/smile/87.jpg)
![](/images/smile/242.jpg)
![](/images/smile/111.jpg)
![](/images/smile/252.jpg)
![](/images/smile/82.jpg)
![](/images/smile/196.jpg)
![](/images/smile/109.jpg)
![](/images/smile/196.jpg)
![](/images/smile/55.jpg)
![](/images/smile/326.jpg)
![](/images/smile/18.jpg)
![](/images/smile/216.jpg)
![](/images/smile/112.jpg)
![](/images/smile/235.jpg)
![](/images/smile/73.jpg)
![](/images/smile/220.jpg)
![](/images/smile/92.jpg)
![](/images/smile/310.jpg)
![](/images/smile/71.jpg)
![](/images/smile/202.jpg)
![](/images/smile/102.jpg)
![](/images/smile/328.jpg)
Background and aims Primary Central Nervous System Lymphoma (PCNSL) is a rare disease, about 2-6.6% of all primary intracranial tumors. The incidence of PCNSL raised recently in both immunocom-promised and immunocompetent people. Surgery is usually ineffective for PCNSL and does not prolong survival because of its infiltrative growth pattern.
![](/images/whatsapp.png)
![](/images/smile/74.jpg)
![](/images/smile/243.jpg)
![](/images/smile/156.jpg)
![](/images/smile/326.jpg)
![](/images/smile/52.jpg)
![](/images/smile/339.jpg)
![](/images/smile/9.jpg)
![](/images/smile/256.jpg)
![](/images/smile/68.jpg)
![](/images/smile/221.jpg)
![](/images/smile/26.jpg)
![](/images/smile/330.jpg)
![](/images/smile/92.jpg)
![](/images/smile/234.jpg)
![](/images/smile/138.jpg)
![](/images/smile/324.jpg)
![](/images/smile/11.jpg)
![](/images/smile/285.jpg)
![](/images/smile/11.jpg)
![](/images/smile/277.jpg)